FIVE PRIME THERAPEUTICS

five-prime-therapeutics-logo

FivePrime is dis­cov­er­ing and devel­op­ing novel ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cally screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a given clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­cally rel­e­vant pro­teins in medically-​​focused assays at the high­est qual­ity stan­dards in the indus­try. ... This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tional “one pro­tein at a time”. The Pro­Screen Engine com­prises the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dented in its effi­ciency, qual­ity, and scale. In addi­tion to DBL Investors, investors include Domain Asso­ciates, Ver­sant Ven­tures, Kleiner Perkins Cau­field and Byers, Texas Pacific Group, Health­Cap, and Advanced Tech­nol­ogy Ventures.

#People #Financial #Website #More

FIVE PRIME THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Medical Therapeutics

Founded:
2001-01-01

Address:
San Francisco, California, United States

Country:
United States

Website Url:
http://www.fiveprime.com

Total Employee:
101+

Status:
Closed

Contact:
415-365-5600

Email Addresses:
[email protected]

Total Funding:
155.04 M USD

Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 ReCAPTCHA Microsoft Azure DNS YouTube DoubleClick.Net ReCAPTCHA V2 Microsoft



Current Advisors List

lewis-williams_image

Lewis Williams Chairman of the Board of Directors @ Five Prime Therapeutics
Board_member

bruce-blazar_image

Bruce Blazar Member of the Scientific Advisors @ Five Prime Therapeutics
Advisor

not_available_image

Lee Douglas Member of the Board of Directors @ Five Prime Therapeutics
Board_member
2002-01-01

ronald-levy_image

Ronald Levy Member of the Scientific Advisors @ Five Prime Therapeutics
Advisor

joseph-goldstein_image

Joseph Goldstein Member of the Scientific Advisory Board @ Five Prime Therapeutics
Advisor
2002-07-01

daniel-hoff_image

Daniel Hoff Member of the Scientific Advisors @ Five Prime Therapeutics
Advisor

franklin-berger_image

Franklin Berger Member of the Board of Directors @ Five Prime Therapeutics
Board_member
2010-09-01

kapil-dhingra_image

Kapil Dhingra Member of the Board of Directors @ Five Prime Therapeutics
Board_member
2015-12-01

Current Employees Featured

lauretta-cesario_image

Lauretta Cesario
Lauretta Cesario Vice President, Human Resources @ Five Prime Therapeutics
Vice President, Human Resources
2009-08-01

michael-kavanaugh_image

Michael Kavanaugh
Michael Kavanaugh Senior Vice President and Chief Scientific Officer @ Five Prime Therapeutics
Senior Vice President and Chief Scientific Officer

thomas-civik_image

Thomas Civik
Thomas Civik President & Chief Executive Officer @ Five Prime Therapeutics
President & Chief Executive Officer
2020-04-01

jim-blair_image

Jim Blair
Jim Blair Director @ Five Prime Therapeutics
Director

lewis-williams_image

Lewis Williams
Lewis Williams Founder, President & CEO @ Five Prime Therapeutics
Founder, President & CEO
2011-08-01

kevin-p-baker_image

Kevin P. Baker
Kevin P. Baker Vice President, Preclinical Development @ Five Prime Therapeutics
Vice President, Preclinical Development
2006-01-01

david-v-smith_image

David V. Smith
David V. Smith Executive Vice President & Chief Financial Officer @ Five Prime Therapeutics
Executive Vice President & Chief Financial Officer
2018-11-01

robert-sikorski_image

Robert Sikorski
Robert Sikorski Vice President @ Five Prime Therapeutics
Vice President

Founder


lewis-williams_image

Lewis Williams

Stock Details


Company's stock symbol is NASDAQ:FPRX

Investors List

kleiner-perkins-caufield-byers_image

Kleiner Perkins

Kleiner Perkins investment in Private Equity Round - Five Prime Therapeutics

versant-ventures_image

Versant Ventures

Versant Ventures investment in Private Equity Round - Five Prime Therapeutics

pfizer-venture-investments_image

Pfizer Venture Investments

Pfizer Venture Investments investment in Venture Round - Five Prime Therapeutics

kleiner-perkins-caufield-byers_image

Kleiner Perkins

Kleiner Perkins investment in Venture Round - Five Prime Therapeutics

j-p-morgan-securities-inc_image

J.P. Morgan Securities Inc.

J.P. Morgan Securities Inc. investment in Venture Round - Five Prime Therapeutics

domain-associates_image

Domain Associates

Domain Associates investment in Venture Round - Five Prime Therapeutics

diamond-capital-company_image

Diamond Capital Company

Diamond Capital Company investment in Venture Round - Five Prime Therapeutics

wellcome-trust_image

Wellcome Trust

Wellcome Trust investment in Venture Round - Five Prime Therapeutics

singapore-bio-innovations_image

Singapore Bio-Innovations

Singapore Bio-Innovations investment in Venture Round - Five Prime Therapeutics

advanced-technology-ventures_image

Advanced Technology Ventures

Advanced Technology Ventures investment in Venture Round - Five Prime Therapeutics

Official Site Inspections

http://www.fiveprime.com

  • Host name: ewhserver1302.edgewebhosting.net
  • IP address: 69.63.140.80
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Five Prime Therapeutics" on Search Engine

Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash

Mar 4, 2021 Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash. Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide. Bemarituzumab is a …See details»

Amgen Successfully Completes Acquisition Of Five Prime …

Apr 16, 2021 THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously …See details»

Amgen Successfully Completes Acquisition Of Five Prime …

Apr 16, 2021 THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced …See details»

Five Prime Therapeutics - Crunchbase Company Profile & Funding

FivePrime is a clinical-stage biotechnology company that develops treatments for cancers. Acquired by. Amgen. San Francisco, California, United States. 101-250. Post-IPO …See details»

Amgen, with rare buyout, pays $1.9B for cancer biotech Five Prime

Published March 4, 2021. Ned Pagliarulo Lead Editor. Amgen Inc. Dive Brief: Amgen will buy cancer drugmaker Five Prime Therapeutics for $1.9 billion in a rare public …See details»

Prime time for Five Prime as Amgen snaps up this once …

Mar 4, 2021 After seeing the biotech's shares soar 300% late last year on positive new data for its midstage gastric cancer program, Amgen has stepped in with a $1.9 billion …See details»

Amgen completes $1.9B acquisition of Five Prime Therapeutics

Apr 16, 2021 Amgen (NSDQ:AMGN) announced today that it successfully completed its $1.9 billion acquisition of Five Prime Therapeutics (NSDQ:FPRX). Thousand Oaks, …See details»

Amgen Completes The Acquisition Of Five Prime …

April 20, 2021 — 11:28 am EDT. Written by Neha Gupta for TipRanks -> Amgen has completed the acquisition of the clinical-stage biotechnology company Five Prime Therapeutics. Amgen had...See details»

Amgen to Acquire Five Prime Therapeutics for $1.9B

Mar 4, 2021 Amgen to Acquire Five Prime Therapeutics for $1.9B. Mar 04, 2021 | staff reporter. Save for later. NEW YORK – Amgen said on Thursday it will acquire Five …See details»

Five Prime Therapeutics Agrees to Sell to Amgen for $1.9 Billion

San Francisco – March 16, 2021 – Cooley advised Five Prime Therapeutics, a publicly traded clinical-stage biotechnology company focused on developing immune modulators …See details»

Five Prime Therapeutics acquired by Amgen - Crunchbase

Mar 4, 2021 Five Prime Therapeutics FivePrime is a clinical-stage biotechnology company that develops treatments for cancers. Acquiring Organization: Amgen Amgen …See details»

Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash

Mar 4, 2021 Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash. Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For …See details»

Five Prime Therapeutics: Understanding Bemarituzumab

Dec 10, 2020 Five Prime Therapeutics is a clinical stage biotech company that is focused on development of novel protein therapies. Five Prime is based in San Francisco, …See details»

Phase 2 FIGHT Trial Results Presented at ASCO GI

Jan 15, 2021 SOUTH SAN FRANCISCO, Calif.-- ( BUSINESS WIRE )-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced clinical results from the global, …See details»

Five Prime Celebrates Many Firsts in Positive Phase II

Nov 12, 2020 Five Prime Therapeutics Inc., in collaboration Zai Lab Limited on the development bemarituzumab, a novel therapy for front-line advanced non HER2+ gastric …See details»

Five Prime Therapeutics Company Profile - Craft

Overview. Five Prime Therapeutics is a biotechnology company focused on developing immuno-oncology and targeted cancer therapies.See details»

Five Prime Therapeutics Appoints Tom Civik as Chief Executive …

Apr 14, 2020 SOUTH SAN FRANCISCO, Calif.-- ( BUSINESS WIRE )-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused …See details»

Five Prime Therapeutics - Funding, Financials, Valuation

$345M. in funding over 9 rounds. Their latest funding was raised on Jan 1, 2018 from a Post-IPO Equity round. Five Prime Therapeutics is registered under the ticker …See details»

Five Prime Therapeutics Announces Collaboration with Roche to …

May 30, 2018 SOUTH SAN FRANCISCO, Calif.– ( BUSINESS WIRE )–Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on …See details»

Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash

Mar 4, 2021 Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash | Business Wire. Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class …See details»